Document is current
Any future updates will be listed below
-
Authors
Mao, Lili
Lai, Yumei
Zheng, Hong
Cui, Ming
Li, Lifeng https://orcid.org/0000-0002-9813-5688
Liu, Ziyi
Zhou, Hongyu
Sun, Linzi
Li, Caili
Wei, Xiaoting
Gu, Junjie
Bai, Xue
Kong, Yan https://orcid.org/0000-0002-2266-7872
Cui, Chuanliang
Chi, Zhihong
Sheng, Xinan https://orcid.org/0000-0001-9359-0975
Lian, Bin
Li, Siming
Yan, Xieqiao
Tang, Bixia
Li, Juan
Zhou, Li https://orcid.org/0000-0002-9331-0600
Wang, Xuan
Guo, Jun
Dai, Jie
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 1 May 2026
First Online: 16 May 2026
Competing interests
: L.Li. is employee of Geneplus-Beijing. L.Si has received speakers’ honoraria from OrienGene, Shanghai Junshi Biosciences, MSD, Novartis, and Roche. J.G. has consulting or advisory roles in Oriengene, Shanghai Junshi Biosciences, Simcere Pharmaceutical Group, Novartis, MSD, Bayer, Roche, and Pfizer. No potential conflicts of interest were disclosed by the other authors.
